ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Prospective Randomized Multicenter Trial (BEST Trial) of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression: Infectious Complications

P. West-Thielke1, A. Shields2, D. Kaufman3, J. Leone4, A. Wiseman5, A. Matas6, T. Sa7, E. King7, R. Alloway2, S. Woodle2

1University of Illinois, Chicago, IL, 2University of Cincinnati, Cincinnati, OH, 3University of Wisconsin, Madison, IL, 4Tampa General Hospital, Tampa, FL, 5University of Colorado, Aurora, CO, 6University of Minnesota, Minneapolis, MN, 7Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2020 American Transplant Congress

Abstract number: 271

Keywords: Adverse effects, Cytomeglovirus, Kidney transplantation, Polyma virus

Session Information

Date: Saturday, May 30, 2020

Session Name: Kidney Infections Excluding Polyoma & Viral Hepatitis

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:15pm-3:27pm

Location: Virtual

Related Abstracts
  • The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
  • Patient-Reported Outcomes in a Prospective Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression Regimens in Kidney Transplantation: A Prospective Analysis Across Two Years

*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) is a prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a standard of care tacrolimus (TAC)-based ESW regimen. The purpose of this study was to compare infectious complications from BELA-based regimens to TAC-based regimens intention to treat, per protocol, and subgroup results.

*Methods: This study was conducted under an FDA IND and IRB approval at each of 8 sites. Adult kidney transplant recipients were eligible for enrollment. All patients received mycophenolate therapy and a five-day steroid taper. 315 patients were randomized to 3 treatment groups: alemtuzumab (Alem) + BELA (Group A), rATG + BELA (Group B), and rATG + TAC (Group C). All infections were collected as adverse events of special interest in this study and were analyzed by intent to treat and per protocol and then by subgroups of BPAR, AA race, BMI ≥ 30 and age ≥ 60.

*Results: Infection outcomes analyses at 24 months (end of study) are presented in tables 1 and 2.

*Conclusions: There were no significant differences in infection rates between the 3 treatment groups in either the intention to treat or per protocol analyses. BELA patients had numerically more BK viremia but less CMV viremia in comparison to TAC patients. Based on the subgroup analyses, the increase in viremia, specifically BK viremia, appears to be driven by BELA patients on r-ATG vs Alem and BELA patients experiencing BPAR or those with BMI ≥ 30. These results indicate that BELA-based regimens under ESW do not appear to increase the risk of infection in comparison to TAC-based regimens under corticosteroid withdrawal. A MVA of risk factors for infection is planned.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

West-Thielke P, Shields A, Kaufman D, Leone J, Wiseman A, Matas A, Sa T, King E, Alloway R, Woodle S. A Prospective Randomized Multicenter Trial (BEST Trial) of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression: Infectious Complications [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/a-prospective-randomized-multicenter-trial-best-trial-of-belatacept-based-cni-and-corticosteroid-free-immunosuppression-infectious-complications/. Accessed January 26, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.